drugset / Trial / NCT01051531

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

NCT01051531

Phase 3 Completed 546 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability and treatment response of paliperidone palmitate administered as once-monthly injections to patients with schizophrenia.

Timeline

Start
2010-04-22
Primary completion
2013-05-17
Completion
2013-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 50 mg Intramuscular
Subject paliperidone palmitate Unknown 75 mg Intramuscular
Subject paliperidone palmitate Unknown 100 mg Intramuscular
Subject paliperidone palmitate Unknown 150 mg Intramuscular

Indications